Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil
about
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structureCrystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transferThe crystal structure and reaction mechanism of Escherichia coli 2,4-dienoyl-CoA reductaseX-ray structure of the complete ABC enzyme ABCE1 from Pyrococcus abyssiThe subnanometer resolution structure of the glutamate synthase 1.2-MDa hexamer by cryoelectron microscopy and its oligomerization behavior in solution: functional implicationsCrystal Structure of the Nitrogenase-like Dark Operative Protochlorophyllide Oxidoreductase Catalytic Complex (ChlN/ChlB)2Molecular basis of dihydrouridine formation on tRNAStrong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patientsA tale of two ferredoxins: sequence similarity and structural differences.Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activityIntragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.Escherichia coli dihydropyrimidine dehydrogenase is a novel NAD-dependent heterotetramer essential for the production of 5,6-dihydrouracil.Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolismThe [4Fe-4S] cluster of quinolinate synthase from Escherichia coli: investigation of cluster ligands.Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.IscR of Rhodobacter sphaeroides functions as repressor of genes for iron-sulfur metabolism and represents a new type of iron-sulfur-binding protein.Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.An extended dsRBD is required for post-transcriptional modification in human tRNAs.Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityA structurally conserved water molecule in Rossmann dinucleotide-binding domains.Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.Insights into Flavin-based Electron Bifurcation via the NADH-dependent Reduced Ferredoxin:NADP Oxidoreductase Structure.Quaternary structure of Azospirillum brasilense NADPH-dependent glutamate synthase in solution as revealed by synchrotron radiation x-ray scattering.Identification of the tRNA-dihydrouridine synthase family.Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.Identification of two novel mutations C79X and R235Q in the dihydropyrimidine dehydrogenase gene in a patient presenting with hematuria.Catabolism of pyrimidines in yeast: a tool to understand degradation of anticancer drugs.Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.
P2860
Q24296496-78D2EF4B-909A-4C5B-AF14-E02167E84903Q27637379-801C1884-2CF4-4C4E-9E1F-0685B1C0C916Q27641609-E56A72F6-2925-44A9-AF31-476CA705C06DQ27649434-F0DEDF13-C0CD-47E7-AD92-7853713ECA40Q27649544-92D2BC42-D1B1-4433-BDC2-72C6F45FAD2EQ27662448-49D1E4EA-58FD-4067-8212-C5D69ACAD95BQ27675860-55EFCD77-BAB2-4C90-B063-23056B2190AFQ28474358-B6BF81F6-D77F-4732-AB3C-63457EC7F9C9Q33239316-33BCF853-3D68-48C1-BC7D-92BCCDD07CE7Q33576321-F5CDEF93-87A2-4413-8056-541A04F776ADQ34134768-A0961708-D17F-4133-9318-0932E9A935CEQ34528619-5CFD4E40-16A7-4068-A174-283EE1687A4CQ34587939-63E2FDAA-D05D-4526-8EA5-D9F512F05B22Q34803393-360EEC54-9D52-445B-82D3-8093BCED5F81Q35584977-22985F4C-F551-40E4-9E31-B62D9E15D19AQ35733964-0B84DFED-2E53-4B99-B7BA-A19ABD49EBC1Q35743233-72034C68-5906-404D-A111-47B2855F1052Q36042698-735BCAD7-EC85-45CD-999F-49BF6E9A642EQ36228090-6F169E5B-1B78-444D-9D07-6589B4B1B739Q36745681-06399B87-40AF-444A-8ECD-1BDACF41BB34Q37290672-50F62641-5220-442F-929C-DC1D2FD251E8Q38269798-16C4AB73-C5D2-4D35-A416-90AF859B43BBQ38300283-98DE6A19-64F3-493D-A500-6B94AB3CA574Q39208906-C99A1012-B662-4254-9FF4-2B00B51C3BCBQ40546452-73E634C1-C701-4946-B198-36CECDC8DA5CQ42584152-1F22A647-0981-4EDD-8730-2FEAAB34BAD0Q44460169-6DFD8A41-C5D8-4E35-A9BE-BD2F40D5944AQ45971732-B6DFF321-4DE8-4587-862A-9EB0F7708766Q46495593-CA279BCB-DCA9-4BAA-802F-70A729D1243EQ46502211-99FC2510-AC96-44E7-9D6E-91C9289A3E5DQ47180241-5143234D-5521-4706-933E-0746206ADC57Q50073098-AA66C26E-3CBC-442B-9507-3750EFDBDBBAQ55497899-89B39A16-4215-4C36-9091-E9534BBF52BA
P2860
Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@ast
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@en
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@nl
type
label
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@ast
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@en
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@nl
prefLabel
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@ast
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@en
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@nl
P2860
P3181
P356
P1433
P1476
Crystal structure of dihydropy ...... nti-cancer drug 5-fluorouracil
@en
P2093
D Dobritzsch
K D Schnackerz
P2860
P304
P3181
P356
10.1093/EMBOJ/20.4.650
P407
P577
2001-02-15T00:00:00Z